Home › Funds › P.A.W. CAPITAL CORP › ABT

P.A.W. CAPITAL CORP position in ABT

ABBOTT LABORATORIES · Health Care

P.A.W. CAPITAL CORP reported holding 56,340 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$5.6M, representing 1.66% of its reported portfolio and ranking #29 among its reported holdings. P.A.W. CAPITAL CORP has disclosed ABT holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)56.34K sh
Reported value held$5.57M
Portfolio Weight1.66%
First reportedQ1 2026
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How P.A.W. CAPITAL CORP's ABT position evolved

P.A.W. CAPITAL CORP first disclosed a stake in ABT in Q1 2026 at 17,960 shares (US$1.8M). The position peaked in Q3 2026 at 56,340 shares, worth US$5.6M. Across 3 filings, P.A.W. CAPITAL CORP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 56,340 shares valued at US$5.6M — a reduction of -2,250 shares quarter over quarter.. Notable position changes include a 226% increase in Q2 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 17.96K $1.83M New
Q2 2026 58.59K $5.32M Add
Q3 2026 56.34K $5.57M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.65B), Charles Schwab Investment Management (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has P.A.W. CAPITAL CORP held ABT?

P.A.W. CAPITAL CORP has disclosed ABT holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is P.A.W. CAPITAL CORP's current position in ABT?

As of Q3 2026, P.A.W. CAPITAL CORP holds 56.34K shares of ABT (ABBOTT LABORATORIES), valued at $5.57M, representing 1.66% of its reported portfolio and ranking #29.

Has P.A.W. CAPITAL CORP been buying or selling ABT?

In the latest 13F filing (Q3 2026), P.A.W. CAPITAL CORP reduced its position in ABT. The position peaked in Q3 2026 at 56.34K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, Charles Schwab Investment Management, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.